Prime Medicine, Inc. (PRME) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $2.00K; Additional Paid in CapitalUSD $1.02B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-9.00K; Retained Earnings (Accumulated Deficit)USD $-979.59M.
- 2026-03-31: Common Stock, Value, IssuedUSD $2.00K; Additional Paid in CapitalUSD $1.01B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.00K; Retained Earnings (Accumulated Deficit)USD $-937.48M.
- 2025-12-31: Common Stock, Value, IssuedUSD $2.00K; Additional Paid in CapitalUSD $1.01B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $82.00K; Retained Earnings (Accumulated Deficit)USD $-888.35M.
- 2025-09-30: Common Stock, Value, IssuedUSD $2.00K; Additional Paid in CapitalUSD $1.00B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $33.00K; Retained Earnings (Accumulated Deficit)USD $-842.27M.
Prime Medicine, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.00K | $1.02B | $-9.00K | $-979.59M | $39.81M | 3 month · $4.87M | 3 month · $338.00K | (m) |
| 2026-03-31 | $2.00K | $1.01B | $-1.00K | $-937.48M | $76.70M | 3 month · $4.64M | (m) | (m) |
| 2025-12-31 | $2.00K | $1.01B | $82.00K | $-888.35M | $120.87M | 12 month · $29.27M | 12 month · $341.00K | (m) |
| 2025-09-30 | $2.00K | $1.00B | $33.00K | $-842.27M | $161.82M | 3 month · $12.75M | (m) | (m) |
| 2025-06-30 | $2.00K | $852.56M | $-10.00K | $-791.69M | $60.86M | 3 month · $6.33M | 3 month · $197.00K | (m) |
| 2025-03-31 | $2.00K | $846.04M | $-15.00K | $-739.10M | $106.92M | 3 month · $5.68M | (m) | (m) |
| 2024-12-31 | $2.00K | $840.36M | $1.00K | $-687.21M | $153.15M | 12 month · $26.07M | 12 month · $837.00K | 12 month · $18.80M |
| 2024-09-30 | $2.00K | $834.42M | $21.00K | $-644.94M | $189.50M | 3 month · $6.83M | 3 month · $401.00K | (m) |
| 2024-06-30 | $2.00K | $789.08M | $-71.00K | $-592.42M | $196.59M | 3 month · $8.09M | (m) | (m) |
| 2024-03-31 | $2.00K | $780.95M | $-95.00K | $-537.09M | $243.77M | 3 month · $5.21M | 3 month · $436.00K | 3 month · $18.80M |
| 2023-12-31 | $2.00K | $624.41M | $-15.00K | $-491.33M | $133.07M | 12 month · $13.91M | (m) | (m) |
| 2023-09-30 | $2.00K | $619.79M | $-149.00K | $-425.69M | $193.96M | 3 month · $4.22M | (m) | (m) |
| 2023-06-30 | $2.00K | $615.35M | $-268.00K | $-374.98M | $240.10M | 3 month · $3.58M | (m) | (m) |
| 2023-03-31 | $2.00K | $611.60M | $-205.00K | $-332.59M | $278.80M | 3 month · $1.68M | (m) | (m) |
| 2022-12-31 | $2.00K | $609.85M | $-384.00K | $-293.20M | $316.27M | 12 month · $6.46M | (m) | (m) |
| 2022-09-30 | $0.00 | $31.27M | $-454.00K | $-253.91M | $-223.10M | 3 month · $1.42M | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | $-195.06M | 3 month · $1.35M | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | $-166.94M | 3 month · $1.12M | (m) | (m) |
| 2021-12-31 | $0.00 | $15.16M | $-27.00K | $-171.38M | $-156.24M | 12 month · $1.75M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | $-94.42M | 3 month · $339.00K | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | $-78.37M | 3 month · $94.00K | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | $-85.31M | 3 month · $206.00K | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | $2.34M | 12 month · $391.00K | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | $-2.60M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |